9 documents

Read All
01:09 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest gene therapies delivering secretion-optimized GAA variants could help treat Pompe’s disease. The gene therapies consist of a liver-tropic adeno-associated viral serotype 8 (AAV8) vector encoding one of two GAA...
Read More
22:59 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest GAA-loaded nanoparticles could help treat Pompe’s disease without generating anti-GAA antibodies associated with resistance to enzyme replacement therapy. The nanoparticles consist of low-immunogenic anionic phosphatidylinositol liposomes loaded with GAA....
Read More
00:10 , Jul 18, 2015 |  BC Extra  |  Company News

Management tracks

Cancer company Exelixis Inc. (NASDAQ:EXEL) named Chris Senner EVP and CFO. Senner was VP of corporate finance at Gilead Sciences Inc. (NASDAQ:GILD). Gene therapy company uniQure N.V. (NASDAQ:QURE) hired Charles Richard as SVP of neuroscience...
Read More
08:00 , Jan 21, 2013 |  BC Week In Review  |  Company News

Oxyrane management update

Oxyrane U.K. Ltd. , Manchester, U.K.   Business: Endocrine/Metabolic   Hired: Susan Flint as executive director and head of clinical operations, formerly program director at Navidea Biopharmaceuticals Inc. ; and Charles Richard as CMO, formerly...
Read More
08:00 , Dec 13, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Yeast cell lines for producing improved enzyme replacement therapies to treat Pompe's disease Genetically modified strains of the yeasts Yarrowia lipolytica and Pichia pastoris may...
Read More
08:00 , Dec 13, 2012 |  BC Innovations  |  Targets & Mechanisms

Muscling up on Myozyme

Oxyrane U.K. Ltd. and BioMarin Pharmaceutical Inc. have separately reported on their next-generation enzyme replacement therapies for Pompe's disease. Both molecules cleared glycogen from mouse muscle better than the marketed drug Myozyme from Sanofi ....
Read More
08:00 , Dec 12, 2011 |  BioCentury  |  Product Development

Muscling in on Myozyme

Oxyrane U.K. Ltd. is developing a next-generation enzyme replacement therapy for Pompe's disease that could improve on Myozyme . By enhancing delivery of enzyme to diseased tissue, the company hopes to reduce dosage and infusion...
Read More
08:00 , Nov 21, 2011 |  BC Week In Review  |  Financial News

Oxyrane completes venture financing

Oxyrane U.K. Ltd. , Manchester, U.K.   Business: Endocrine/Metabolic   Date completed: 11/17/11   Type: Venture financing   Raised: $26.5 million   Investors: Forbion Capital Partners; Morningside Group; New Science Ventures  ...
Read More
01:25 , Nov 18, 2011 |  BC Extra  |  Financial News

Oxyrane raises $26.5M in a series D

Oxyrane U.K. Ltd. (Manchester, U.K.) raised $26.5 million in a series D round. New investors Forbion Capital Partners and Morningside Group joined existing investor New Science Ventures. Oxyrane is developing enzyme replacement therapies to treat...
Read More